Panbela Therapeuticsの収入

Panbela Therapeuticsの収入 は何ですか。

Panbela Therapeutics Inc.の収入 は-23.51$です。

収入 の定義は何ですか。

普通株主に帰属する当期純利益は、純利益から優先配当金を差し引いた金額です。優先配当

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

NASDAQのセクタHealth Careにおける収入 の企業と比べるPanbela Therapeutics

Panbela Therapeuticsは何をしますか。

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Panbela Therapeuticsと類似の収入